GOTHENBURG, Sweden, June 11, 2021 /PRNewswire/ -- Vicore Pharma Holding AB (publ) ("Vicore"), a rare disease pharmaceutical company developing innovative medicines for fibrotic lung disorders such as idiopathic pulmonary fibrosis (IPF), today announces that the U.S. Food and Drug Administration (FDA) has accepted the Investigational New Drug (IND) application for the company's lead asset, the orally available angiotensin II type 2 receptor (AT2R) agonist C21, for the treatment of COVID-19. The active IND enables initiation of US sites in Vicore's pivotal phase 3 trial, ATTRACT-3.
ATTRACT-3 trial is a randomized, double-blind, placebo-controlled, multinational, phase 3 trial that will include 600 adult patients hospitalized with COVID-19 requiring oxygen support but not mechanical ventilation. The primary objective is to evaluate the effect of C21 on recovery from COVID-19. Vicore's Phase 2 trial (ATTRACT) in COVID-19 showed that C21 significantly reduced the extended need for supplemental oxygen therapy, indicating faster recovery on C21 compared to placebo.
In ATTRACT-3, patients will be randomized to receive 100 mg C21 or placebo twice daily on top of standard of care (SoC) for 14 days and patients will be followed for 60 days. Trial preparations are currently ongoing in countries in North America, South and Central America, Europe, Africa and Asia. Topline results from ATTRACT-3 are expected during the first quarter of 2022.
"Morbidity and mortality in COVID-19 are still significant, particularly in moderate to severe disease, and our earlier trial indicates that C21 has the potential to improve respiratory outcomes and promote recovery in these patients," said Carl-Johan Dalsgaard, CEO of Vicore. "The FDA's acceptance of our first IND with C21 represents an important milestone in preparing our global phase 3 trial."
C21 in COVID-19 ? improved respiratory outcomes
Results from the phase 2 ATTRACT study on 106 hospitalized patients with COVID-19, showed a significantly reduced risk for the need of supplemental oxygen (90% compared to placebo at day 14; P=0.003) and numerically fewer deaths and cases of patients requiring mechanical ventilation.
C21, a first-in-class AT2R agonist
C21 is a first-in-class, orally available, low molecular weight, angiotensin II type 2 receptor (AT2R) agonist that activates the "protective arm" of the renin-angiotensin system (RAS). The compound has shown robust effects in human idiopathic pulmonary fibrosis (IPF) lung slices and a phase 2 proof-of-concept study in IPF is currently ongoing. Given that AT2R agonism has therapeutic potential in several additional indications with significant unmet medical needs, Vicore has intensified the efforts to develop proprietary follow-up molecules with differentiated profiles.
For further information, please contact:
Carl-Johan Dalsgaard, CEO
Phone: +46 70 975 98 63
This information was submitted for publication on June 11, 2021 at 08.00 CET.
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
Vicore announces FDA acceptance for pivotal phase 3 trial of C21 in COVID-19
SOURCE Vicore Pharma Holding AB
These press releases may also interest you